{
    "id": "26920650",
    "text": "Lavoltidine (INN, USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents. ==See also== * H2 receptor antagonist * Sufotidine (analogous sequence in which sulfone replaces the hydroxyl group) ==References== Category:Abandoned drugs Category:Primary alcohols Category:Amines Category:H2 receptor antagonists Category:Piperidines Category:Triazoles Category:Phenol ethers ",
    "title": "Lavoltidine"
}